Biotechnology

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

SAN FRANCISCO and SUZHOU, China, May 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-05-19 08:00 3517

2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH

——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...

2025-05-17 08:41 3881

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...

2025-05-16 23:10 4359

Visionary: Pioneering a New Era in Cancer Screening

TORONTO, May 16, 2025 /PRNewswire/ -- Recently, Visionary has achieved a significant breakthrough in the field of early cancer screening and home self - testing technologies, attracting widespread attention from the industry. American Precision Biotech Inc. is a subsidiary of Visionary Holdings. ...

2025-05-16 21:30 2615

Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan

NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions , a leader in prenatal and oncology genetic testing, andNEWCL Biomedical Laboratory , Taiwan's pioneering clinical laboratory with LDTs certification, have joine...

2025-05-16 19:06 3027

Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch

* Official debut signals full-scale entry into global markets * Biome Barrier Cream Mist earns 'Amazon's Choice' designation SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ ( www.theui...

2025-05-16 16:00 2436

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...

2025-05-16 11:57 2069

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Departmen...

2025-05-16 09:00 2735

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, tod...

2025-05-15 21:13 2635

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML * A pooled safety and efficacy analysis of two Phase I/II studies ...

2025-05-15 18:09 2346

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

HONG KONG, May 15, 2025 /PRNewswire/ -- Artificial intelligence has rapidly evolved from academic theory into a transformative force in pharmaceutical R&D. From early QSAR models to neural networks, and now to AlphaFold3, AI has progressively unlocked deeper biological insights. By integrating st...

2025-05-15 15:02 2173

Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions

BEIJING, May 15, 2025 /PRNewswire/ -- Tsingke Biotech proudly participated in theAACR Annual Meeting 2025, held this April in Chicago, USA. As one of the world's premier events in oncology research, AACR gathered global leaders from academia and industry to explore the future of cancer diagnostic...

2025-05-15 14:12 1910

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

— Accelerating Expansion Across Human and Veterinary Health Through Innovation and Strategic Collaboration BRUSSELS, May 15, 2025 /PRNewswire/ -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...

2025-05-15 13:04 1795

STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing

As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...

2025-05-15 11:30 2050

Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat

* Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. * The company has received the EOP2 meeting minutes, confirming the primar...

2025-05-14 13:38 1983

GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California

YONGIN, South Korea, May 14, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that its U.S. subsidiary, ABO Holdings, has received FDA approval for its plasma collection center located inCalexico, California. Following the successful U.S. launch of ALYGLO (im...

2025-05-14 13:21 1939

Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future

SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis , a world-leading biosolutions company, co-hosted its "Unlocking Value for a Sustainable Future" Partnering Day 2025 inSingapore on May 7 together with Novo Holdings and Flagship Pioneering. The event focused on resha...

2025-05-14 13:17 2415

Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services

This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Lead...

2025-05-14 13:00 1481

Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD

* Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo. SING...

2025-05-14 10:30 2200

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

* Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections * Demonstrated its Efficacy and Safety through previous Clinical Trials * Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotech...

2025-05-13 20:00 1775
1 ... 43444546474849 ... 342

Week's Top Stories